In Cardiovascular Devices, Who's Next?
Whereas much of the activity in cardiovascular M&A in the past seems to have come from a euphoric sense of the promise of cardiovascular medicine, the more recent moves have an air of frustrated hopes. The two large deals announced most recently, Boston Scientific Corp.'s acquisition of Pfizer Inc.'s Schneider angioplasty business and Medtronic Inc.'s purchase of external defibrillator company Physio-Control International corp. seem to have been driven by sellers looking for exit strategies as much as buyers looking for new opportunities.
You may also be interested in...
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.